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studies or participate in joint projects, whereas 69% plan to conduct HSR studies in 
the near future. All these numbers increased since the last surveys. ConClusions: 
The results of the survey clearly pointed out the high and still increasing importance 
of HSR and real-life studies also in the health care industry. Although a considerable 
amount of uncertainty concerning the specific methodological requirements remain 
it is widely accepted that the quality of data and analyses is crucial for acceptance 
by payers. As HSR projects require considerable human and financial resources alli-
ances and joint projects between industry, academia and payer are aspired.
PHP61
IntegratIon of Cost–effeCtIveness assessment In tHe market aCCess 
sCHeme of Drugs anD meDICal DevICes In franCe
Rumeau-Pichon C., Harousseau J.L.
Health Economics and Public Health Department S, Health Economics and Public Health 
Committee C
Haute Autorité de santé, Saint-Denis La Plaine, France
objeCtives: In France, drugs and medical devices costs concern an important part 
of health care expenditure. Several reforms have been put in place over the past 
years in order to limit these expenditures, in particular price cutting policy. Cost-
effectiveness assessment was integrated in France in the market access scheme 
of health products by the Social Security Financing Act for 2012 and is required 
since October 3rd 2013. This new mission was assigned to the Health Economics 
and Public Health Committee (CEESP) of the French National Authority for Health 
(HAS) and is become compulsory for innovative health products and are likely to 
have a significant impact on the health insurance expenditures. The objectives of 
this work were to see how the cost-effectiveness assessment has been integrated in 
France and to discuss the impact of this assessment on the health products market 
access. Methods: The work consists in analyzing the process of the economic 
evaluation achieved by the HAS since October 3rd 2013. Results: Economic evalu-
ation is a new step in the market access scheme. In order to respect the legislated 
timeframe of 90 days, it is simultaneously conducted with the medical assessment 
by the Transparency Commission of the HAS. For each health products, an efficiency 
opinion is delivered by the CEESP. It presents the methodological conformity accord-
ing to HAS guidelines and a conclusion about the efficiency, on the basis of the 
Incremental Cost-Effectiveness Ratio (ICER). Currently, 15 dossiers were eligible for 
cost-effectiveness assessment. First assessments permit to confirm that the pro-
cedure is operational. The average processing time was 94,8 days. ConClusions: 
In France without efficiency threshold value, the CEESP can’t conclude absolutely 
on the efficiency of health product. We don’t know how the ICER will be considered 
by the French Healthcare Products pricing Committee (CEPS) at the time of pricing 
negotiation with the pharmaceutical industry.
PHP62
analysIs of Cost-effeCtIveness assessments In franCe By tHe frenCH 
natIonal autHorIty for HealtH (Has)
Rumeau-Pichon C., Harousseau J.L.
Health Economics and Public Health Department S, Health Economics and Public Health 
Committee C.
Haute Autorité de santé, Saint-Denis La Plaine, France
objeCtives: In France, cost-effectiveness assessment is required since October 3rd 
2013 for innovative health products and are likely to have a significant impact on 
the health insurance expenditures. The objective of this work is to report first cost-
effectiveness assessments, achieved by the Health Economics and Public Health 
Committee (CEESP) of the French National Authority for Health (HAS). Methods: 
The investigation consists in analyzing medico-economic dossiers submitted at 
the CEESP between October 2013 and October 2014. This analysis is based on the 
opinion delivered by the CEESP, the methodology used in the model and the pro-
cess of the assessment achieved by the HAS. Results: At the time of writing the 
abstract, 15 dossiers were eligible for cost-effectiveness assessment. All dossiers 
were based on cost-utility models. Two dossiers presented a negative opinion due 
to the methodological conformity according to HAS guidelines. For dossiers with 
a positive opinion, the Incremental Cost-Effectiveness Ratio (ICER) were between 
5 866€ /QALY (for a subgroup analysis) and 194 531 € /QALY. Main methodological 
reserves made by the CEESP concerned comparators, time horizon, robustness of 
clinical data, utility measures. The average processing time was 94,8 days. For the 
moment, no price has been published in the Official Journal. ConClusions: The 
first assessments permit to confirm that the procedure is operational. In light of 
these first assessments, an update of the HAS methodological guidelines should 
be done. In France, without efficiency threshold value, the CEESP can’t conclude 
absolutely on the efficiency of health products. Thus, we don’t know what will be 
the place of the ICER in the pricing negotiation between the pharmaceutical industry 
and the French Healthcare Products pricing Committee (CEPS).
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objeCtives: The objective of this research is to provide an overview of the regula-
tory process of medical devices in China. Potential challenges related to medical 
device registration and major policy changes are highlighted especially since the 
restructuring of the China FDA in March 2013. The results of this research are aimed 
at informing regulatory bodies, health policy decision makers, national and interna-
tional Health Technology Assessment networks, as well as medical devices manu-
facturers. Methods: A systematic review was conducted from 2009-2013 to identify 
the challenges and opportunities in the Chinese medical device regulatory process 
searching the PubMed, Science Direct, Scopus databases and Zhongguozhiwang. 
The PRISMA guidelines were applied for the search. In addition, an analysis of 
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objeCtives: Therapeutic Positioning Reports (TPRs) were introduced to the 
Spanish P&R process in May 2013. TPRs evaluate comparative efficacy and safety 
and introduce usage and monitoring criteria for new drugs and existing drugs seek-
ing reimbursement. The procedure was set-up by the Spanish Medicines Agency 
(AEMPS) and the Ministry of Health with the aim to accelerate the P&R process 
and to generate a single, national relative effectiveness report avoiding additional 
regional evaluations, contributing to reducing the long-delays in market access 
timelines experienced in the last few years. The objective of this ongoing work 
is to describe and analyze both the metrics of the process and the contents and 
results of TPRs. Methods: Descriptive study based on public information available 
from the European and Spanish Medicines Agencies (May 2013-ongoing). Results: 
From June 2013 to May 2014 the Therapeutic Positioning Coordinating Group 
(TPCG) has officially launched 60 TPR plus 7 use protocols (UP) at the request of 
the Interministerial Price Council (IMPC). 75% of TPR involve new chemical enti-
ties (82% of those with a positive opinion from the CHMP between May 2013-April 
2014) and assess a single entity (48% specialty care) indicated, mainly, for patients 
with neoplastic (28%) and endocrine (18%) diseases. All UP affect targeted therapies 
with approval between Jan2010-Dec2012. Since its establishment in May 2013, the 
TPCG has released 26 TPR (57% of those expected according to the pre-established 
procedure -3 months working time) with a median release time of 7,1 months. Only 
1 has been published. The rest await for P&R decisions. Other 5 pilots have been 
published in parallel. In total 5 TPR recommend to further restrict the European 
label. ConClusions: TPR are not being released at the expected rate. Follow up is 
necessary to predict its impact in P&R and market access in regions across Spain.
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objeCtives: Medical devices constitute a set of important health technologies for 
the care of patients. While there are similarities between some reimbursement 
systems, each market has its own unique characteristics. This article focuses on 
the reimbursement procedures for medical devices in the DACH countries (Austria, 
Germany, Switzerland), and aims at finding commonalities in payer requirements 
and reimbursement pathways. Methods: Reimbursement application pathways 
for inpatient and outpatient medical devices were evaluated for Austria, Germany 
and Switzerland. The key items being analysed for similarities and differences in 
each setting were transparency, clinical and health economic evidence require-
ments, submission timelines and the length of the whole reimbursement appli-
cation process. Results: In the inpatient setting, the evidence requirements for 
clinical data are different between the analysed countries: The lowest clinical evi-
dence requirements are seen in Germany, while the highest are given in Switzerland 
(in some scenarios). In terms of health economics the requirements are medium 
to low. A medium rating was given for Austria and Switzerland (in some scenarios) 
as a health economic analysis is required (e.g. cost comparison), and a low rat-
ing was applied to Germany as limited economic information (cost assessment/
comparison) needs to be submitted. The length of the application process is well 
defined in Austria and Germany and vague in Switzerland. In the outpatient setting 
the requirements for clinical and health economic data are significantly increas-
ing. Clinical requirements are getting close to pharmaceutical methods whereas 
health economic evidence is requested in all DACH countries. The length of the 
reimbursement process is not clearly defined in all three countries. ConClusions: 
Despite varying reimbursement processes within the DACH region, there are some 
important similarities between the evidence requirements which may help manu-
facturers to guide market access and reimbursement strategy decisions in order 
to drive successful submissions and applications of innovative medical devices.
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objeCtives: The necessity for manufacturer of pharmaceuticals and medical 
devices seem to deal with health services research (HSR). Health care reform acts 
and revisions of HTA method guidance documents in many European countries 
continue to point out the importance of real-life consequences. The objective of the 
study was to evaluate the self-reported importance and the own activities of phar-
maceutical companies in Germany concerning health services research. Methods: 
Between December 2013 and February 2014 an online survey among members of 
the German Pharmaceutical Industry Association (BPI) was accomplished. Similar 
surveys were conducted in 2009 and 2011. Results: 59% of 109 addressed com-
panies took part in the survey. The participants were representative for Germany 
concerning research-orientation, size and type of products. For 88% of the participat-
ing companies HSR is of importance. This high rate remained constant compared 
to the last surveys. For most of the companies HRS yields valuable contributions 
for the negotiations with payers (96%), in the AMNOG evaluation process (89%) and 
for optimization of placement of marketed products (94%). 50% of the companies 
conducted HSR studies over the last years, respectively are currently conducting HSR 
